Bidirectional Risk Association Between Hidradenitis Suppurativa and Inflammatory Bowel Disease
DOI:
https://doi.org/10.2340/actadv.v105.43657Keywords:
Hidradenitis suppurativa, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Matched cohort study, TriNetXAbstract
Hidradenitis suppurativa is an inflammatory skin disease of the pilosebaceous unit encompassing painful, recurrent, and malodorous abscesses, inflammatory nodules, dermal sinus tracts, and cicatrices. Hidradenitis suppurativa has been linked to several comorbidities, including inflammatory bowel disease, though evidence is limited by small sample sizes and possible bidirectional associations remain uncertain. A large-scale, propensity-score matched retrospective cohort study was performed using the TriNetX platform to investigate bidirectional risks between hidradenitis suppurativa and inflammatory bowel disease. Data included over 200,000 hidradenitis suppurativa patients and 3.3 million inflammatory bowel disease patients. Hidradenitis suppurativa was associated with a 36% increased risk of developing any inflammatory bowel disease diagnosis within 5 years of diagnosis (hazard ratio [HR] 1.356, confidence interval [CI] 1.313–1.401), with the highest risk of Crohn’s disease (HR 2.501, CI 2.209–2.832), followed by ulcerative colitis (UC) (HR 1.722, CI 1.536–1.930), and other/unspecified inflammatory bowel disease (HR 1.349, CI 1.306–1.394). Conversely, individuals with any inflammatory bowel disease diagnosis had a 31% increased risk of developing hidradenitis suppurativa (HR 1.313, CI 1.274–1.353), with Crohn’s disease showing the strongest association (HR 2.441, CI 2.242–2.658), followed by UC (HR 1.493, CI 1.358–1.642). These findings highlight the bidirectional risk relationship between hidradenitis suppurativa and inflammatory bowel disease, demonstrating that the likelihood of developing either condition is significantly elevated in patients already diagnosed with the other.
Downloads
References
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191–194. DOI: https://doi.org/10.1016/S0190-9622(96)90321-7
Alotaibi HM. Incidence, risk factors, and prognosis of hidradenitis suppurativa across the globe: insights from the literature. Clin Cosmet Investig Dermatol 2023; 16: 545–552. DOI: https://doi.org/10.2147/CCID.S402453
Chen WT, Chi CC. Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol 2019; 155: 1022–1027. DOI: https://doi.org/10.1001/jamadermatol.2019.0891
Phan K, Tatian A, Woods J, Cains G, Frew JW. Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis. Int J Dermatol 2020; 59: 221–228. DOI: https://doi.org/10.1111/ijd.14697
Shalom G, Freud T, Yakov GB, Khoury R, Dreiher J, Vardy DA, et al. Hidradenitis suppurativa and inflammatory bowel -disease: a cross-sectional study of 3,207 patients. J Invest Dermatol 2016; 136: 1716–1718. DOI: https://doi.org/10.1016/j.jid.2016.04.003
Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol 2018; 32: 1784–1790. DOI: https://doi.org/10.1111/jdv.15071
Aparício Martins I, Figueira Vilela B, Cabete J. Diagnostic delay in hidradenitis suppurativa: still an unsolved problem. Skin Appendage Disord 2024; 10: 129–132. DOI: https://doi.org/10.1159/000534845
Jayasooriya N, Baillie S, Blackwell J, Bottle A, Petersen I, Creese H, et al. Systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Aliment Pharmacol Ther 2023; 57: 635–652. DOI: https://doi.org/10.1111/apt.17370
Palchuk MB, London JW, Perez-Rey D, Drebert ZJ, Winer-Jones JP, Thompson CN, et al. A global federated real-world data and analytics platform for research. JAMIA Open 2023; 6: ooad035. DOI: https://doi.org/10.1093/jamiaopen/ooad035
Curman P, Kridin K, Zirpel H, Hernandez G, Akyuz M, Thaci D, et al. COVID-19 infection is associated with an elevated risk for autoimmune blistering diseases while COVID-19 vaccination decreases the risk: a large-scale population-based cohort study of 112 million individuals. J Am Acad Dermatol 2025; 92: 452–463. DOI: https://doi.org/10.1016/j.jaad.2024.10.063
Kolkhir P, Bieber K, Hawro T, Kridin K, Ludwig MA, Olbrich H, et al. Mortality in adult patients with chronic spontaneous urticaria: a real-world cohort study. J Allergy Clin Immunol 2025; 155: 1290–1298. DOI: https://doi.org/10.1016/j.jaci.2024.11.036
Kridin K, Bieber K, Vorobyev A, Moderegger EL, Olbrich H, Ludwig MA, et al. Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis. EBioMedicine 2025; 111: 105485. DOI: https://doi.org/10.1016/j.ebiom.2024.105485
Sempere L, Bernabeu P, Cameo J, Gutiérrez A, García MG, García MF, et al. Gender biases and diagnostic delay in inflammatory bowel disease: multicenter observational study. Inflamm Bowel Dis 2023; 29: 1886–1894. DOI: https://doi.org/10.1093/ibd/izad001
Sun Q, Broadaway KA, Edmiston SN, Fajgenbaum K, Miller-Fleming T, Westerkam LL, et al. Genetic variants associated with hidradenitis suppurativa. JAMA Dermatol 2023; 159: 930–938. DOI: https://doi.org/10.1001/jamadermatol.2023.2217
Annese V. Genetics and epigenetics of IBD. Pharmacol Res 2020; 159: 104892. DOI: https://doi.org/10.1016/j.phrs.2020.104892
Janse IC, Koldijk MJ, Spekhorst LM, Vila AV, Weersma RK, Dijkstra G, et al. Identification of clinical and genetic parameters associated with hidradenitis suppurativa in inflammatory bowel disease. Inflamm Bowel Dis 2016; 22: 106–113. DOI: https://doi.org/10.1097/MIB.0000000000000579
Canoui-Poitrine F, Thuaut AL, Revuz JE, Viallette C, Gabison G, Poli F, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol 2013; 133: 1506–1511. DOI: https://doi.org/10.1038/jid.2012.472
Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol 2018; 31: 14–23. DOI: https://doi.org/10.20524/aog.2017.0208
Bao B, Zhu C, Shi J, Lu C. Causal association between inflammatory bowel disease and hidradenitis suppurativa: a two-sample bidirectional Mendelian randomization study. Front Immunol 2023; 14: 1071616. DOI: https://doi.org/10.3389/fimmu.2023.1071616
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329–342. DOI: https://doi.org/10.1038/nri3661
Jiang SW, Whitley MJ, Mariottoni P, Jaleel T, MacLeod AS. Hidradenitis suppurativa: host-microbe and immune pathogenesis underlie important future directions. JID Innov 2021; 1: 100001. DOI: https://doi.org/10.1016/j.xjidi.2021.100001
Navarro-Compán V, Puig L, Vidal S, Ramírez J, Llamas-Velasco M, Fernández-Carballido C, et al. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Front Immunol 2023; 14: 1191782. DOI: https://doi.org/10.3389/fimmu.2023.1332177
Cronin P, McCarthy S, Hurley C, Ghosh TS, Cooney JC, Tobin AM, et al. Comparative diet-gut microbiome analysis in Crohn’s disease and hidradenitis suppurativa. Front Microbiol 2023; 14: 1289374. DOI: https://doi.org/10.3389/fmicb.2023.1289374
McCarthy S, Barrett M, Kirthi S, Pellanda P, Vlckova K, Tobin AM, et al. Altered skin and gut microbiome in hidradenitis suppurativa. J Invest Dermatol 2022; 142: 459–468. DOI: https://doi.org/10.1016/j.jid.2021.05.036
Zee HH van der, Horvath B, Jemec GBE, Prens EP. The association between hidradenitis suppurativa and Crohn’s disease: in search of the missing pathogenic link. J Invest Dermatol 2016; 136: 1747–1748. DOI: https://doi.org/10.1016/j.jid.2016.05.102
Wang B, Yang W, Wen W, Sun J, Su B, Liu B, et al. Gamma-secretase gene mutations in familial acne inversa. Science 2010; 330: 1065. DOI: https://doi.org/10.1126/science.1196284
Melnik BC, Plewig G. Impaired Notch signalling: the unifying mechanism explaining the pathogenesis of hidradenitis suppurativa (acne inversa). Br J Dermatol 2013; 168: 876–878. DOI: https://doi.org/10.1111/bjd.12068
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Louise Lönndahl, Maria Najeeb, Hassan Killasli, Lennart Emtestam, Ralf J. Ludwig, Philip Curman
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
